NX
NextCure, Inc.
NXTC · NASDAQ
$5.12 +0.59% (+$0.03)
1M -39.55%
Market Cap $18.4M
P/E Ratio -
Div. Yield -
ROE 175.46%
Bulios Fair Price
$5.56
8.6% upside
Current Price
$5.12
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NXTC is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 1.51x
P/FFO N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 40.70%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 175.46%
ROA 188.98%
Asset turnover 0.00x
Debt
97 /100
Low Current ratio 3.47x
Debt/Equity 0.35x
Net debt/EBITDA N/A
Stability
61 /100
Moderate EPS volatility 3.16%
Profitable years 0
Beta 1.34x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NXTC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael S. Richman
Employees
40
Headquarters
Beltsville
Upcoming events
04 NOV
Earnings
Upcoming earnings report